glp-1 max ShailyPen Axiom and ShailyPen Neo (GLP-1 pens) | Shaily PURE HEALTH MAX Ultimate GLP-1

Hyperglycemia may not cause any symptoms, although in some cases it may cause excessive urination (polyuria) and increased thirst, as we discussed in fall quarter (see Polyuria in Diabetes Mellitus)

Overview of main clinical studies for MASLD/MASH with GLP-1 receptor agonists and dual or triple agonists targeting glucagon/GIP/GLP-1 receptors Liraglutide Liraglutide, a once-daily GLP-1 receptor agonist with authorized indications for type 2 diabetes and obesity, was evaluated in the LEAN trial (NCT01237119), a phase 2 randomized controlled study enrolling 52 adults with biopsy-proven MASH [22]

Vella A, Shah P, Basu R, Basu A, Holst JJ, Rizza RA

Clinical Trial Results STEP trials (Semaglutide Treatment Effect in People with obesity): Average weight loss of ~15% of total body weight